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Abstract 
 
Background: Antiretroviral therapy (ART) during acute HIV infection (AHI) restricts the HIV 
reservoir, but additional interventions will be necessary to induce a cure.Intravenous 
immunoglobulin (IVIG) is not HIV-specific but is safe and temporarily reduces HIV reservoir in 
chronic HIV infection. We present a randomised controlled trial to investigate whether IVIG 
plus ART in AHI reduces the HIV reservoir and immune activation compared with ART alone.  
Methods: Ten males with AHI (Fiebig II-IV) initiated ART (TNF/FTC/DRVr/RAL) at HIV-1 
diagnosis and were randomised to ART alone or ART plus 5 days IVIG, once virally 
suppressed (w19). Blood samples were evaluated for viral reservoir, immune activation, 
immune exhaustion and microbial translocation. Flexible sigmoidoscopy was performed at 
weeks 19, 24 and 48, and gut proviral DNA and cell numbers determined.  
Results: IVIG was well tolerated and no viral blips (>50 copies/ml) occurred during IVIG 
therapy. From baseline to w48, total HIV DNA in PBMCs (cases: -3.7 log10 copies/million CD4 
cells, controls -3.87 log10 copies/million CD4 cells) declined with no differences observed 
between the groups (p=0.49). Declines were observed in both groups from w19 to w48 in 
total HIV DNA in PBMCs (p=0.38), serum low copy RNA (p=0.57) and gut total HIV DNA (p 
=0.55) but again there was no significant differences between arms. 
Plasma levels of CRP, levels of immune activation, immune exhaustion, microbial 
translocation and CD4:CD8 ratio were similar between arms for all comparisons. 
Conclusion: Although safe, IVIG in AHI did not impact total HIV DNA, immune function or 
microbial translocation in peripheral blood or gut tissue. 
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Background: 
Despite the huge success of antiretroviral therapy (ART), a cure is needed to reduce ongoing 
morbidity and unsustainable costs of maintaining those living with HIV on lifelong ART. 
Current antiretroviral therapy potently suppresses human immunodeficiency virus type 1 
(HIV-1) replication, however proviral infection still persists in a small pool of latently infected 
cells (the ‘reservoir’). Targeting the reservoir is critical for a HIV cure and evidence suggests 
that a combination of interventions will be required [1].  
 
Immediate ART following infection can minimize the size and complexity of the latent 
reservoir [2,3] and in a minority of individuals can lead to post-treatment control [4,5]. 
Additional interventions are required; proposed strategies include the passive infusion of 
neutralizing antibodies [6] and kick and kill approaches to induce HIV reactivation to reveal 
hidden virus [7]. Intravenous immunoglobulin is used in a variety of autoimmune conditions 
and has been shown in chronic HIV infection to temporarily reduce viral reservoir in the 
presence of ART [7,8].  
 
We propose that giving intravenous immunoglobulin at acute infection will induce a change 
in reservoir before the set point has been reached, thus conferring a long term benefit on 
viral reservoir. We investigated whether the addition of immunoglobulin could cause 
reactivation of virus which would be re-suppressed by resident ART thereby reducing long 
term immune activation and HIV viral reservoir.  
 
Methods 
This was a prospective, proof of concept 48- week randomized study.  Acutely HIV-infected 
adults, defined as HIV antibody negative with p24/PCR DNA positive or HIV antibody positive 
with a previous HIV negative test in the preceding 3 months or HIV incident assay 
(estimating virus acquired within 3 months) were enrolled at a single site over four months. 
At enrolment all subjects initiated 4-drug antiretroviral therapy (tenofovir, entricitabine, 
ritonavir boosted darunavir and raltegravir). Blood samples were collected at baseline, week 
4, 12, 19, 24, 36 and 48. Individuals who had an undetectable HIV viral load (< 50 copies HIV 
RNA/ml) at week 19 were randomised to receive a five day infusion of intravenous 
immunoglobulin (Octagam® 10%: 30g per day) or to remain in the ART alone arm. All 
individuals had optional rectal biopsies obtained by flexible sigmoidoscopy at w19, w24 and 
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w48.  The study was approved by the National Research Ethics Service (12/LO/0977) and 
registered at the European Clinical Trials Database (2011-001982-42).  
 
Ten subjects were recruited within four months; one individual was subsequently withdrawn 
and replaced as virological suppression had not been achieved by w19.  
 
Reservoir and Residual viraemia 
Low copy viral load was measured with an internally controlled ultrasensitive quantitative 
real-time RT-PCR able to detect 3 copies/ml. Purified peripheral blood CD4 T cells were 
analyzed by qPCR for HIV-1 DNA (Total and Integrated) as reported elsewhere [3]. 
 
For preparation of the gut biopsies for HIV reservoir quantitation, a commercial kit was used 
(Qiagen, Cat. No. 56404), and the manufacturer’s protocol modified as follows to ensure 
maximum yield of DNA. Biopsy sections were removed from paraffin blocks using a scalpel 
and placed into 1.5ml micro centrifuge tubes. Samples were washed repeatedly with xylene 
and ethanol until the precipitate had disappeared, then dried at room temperature.  Biopsy 
sections were incubated at 37°C and DNA extracted using a commercial kit (QIAAMP DNA 
FFPE Tissue Extraction Kit, ID 56404, Qiagen (Hilden, Germany)). The resulting DNA was 
eluted into 200ųl and analysed by qPCR using the same assays for peripheral blood CD4 cells 
detailed above. 
 
Bacterial translocation 
Plasma bacterial 16s DNA was quantified by real time PCR [9]. All samples were run in 
duplicate. 
 
Immune activation and lymphocyte subsets  
PBMC were stained with the anchor markers (CD3- VioBlue, CD4(VIT4)-VioGreen, CD8-APC) 
(Miltenyi Biotec) and a Live/Dead marker Near IR- APC-Cy7 (ThermoFisher Scientific) plus 
either an activation panel (CD25(3G10)-PE, CD38-PE-Vio770, CD69-FITC, Anti-HLA-DR-
PerCP)(Miltenyi Biotec) or an exhaustion panel (TIGIT-PE, TIM-3-FITC, LAG-3-PerCPeF710, 
PD1-PE-Cy7) (eBioscience). Cells were run on a MACSQuant and analysed with FlowJo 
software v10 (Miltenyi Biotec).  
 
 Immunohistochemistry  
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Rectal biopsy sections were stained for CD4 (goat polyclonal, Novus Biologicals) and CD8 
antibodies (rabbit polyclonal, Abcam). Images were analysed in ImageJ and the distribution 
of cells determined as described elsewhere [9]. 
 
Statistical Analysis  
All outcome measures were compared using the paired T-test after confirming normal 
distribution of variables. The primary outcome was week 0 to week 48 and secondary 
outcomes from week 19 (randomisation) to week 48.  
 
Results  
Patient characteristics 
All 10 individuals were male. The mean age was 31 years, mean (SD) baseline CD4 was 593.3 
cells/ml (177.68), HIV viral load 6.0 log10 copies/ml (6.35) and CD4:CD8 ratio = 0.61 (0.3) 
(Table 1). All individuals had wild type virus and maintained virological suppression from 
w19 to w48. Immunoglobulin therapy was well tolerated and no viral blips (above < 50 
copies/ml) occurred during IVIG therapy. Spearman's rank correlation showed a non-
statistically significant negative relationship between baseline viral load and baseline total 
HIV DNA (correlation coefficient = -0.21: p= 0.56). 
 
Primary outcome: 
- HIV-1 reservoir 
Total HIV DNA in PBMCs decreased in both arms from baseline to w48 (immunoglobulin arm 
-3.70 log10 copies/million CD4 cells ; control arm -3.87 log10 copies/million CD4 cells) with no 
significant difference in change between the arms (CI -6548.5,11482.97;p=0.49). 
Furthermore no significant change between the arms was observed from w19 to w48 for 
total HIV DNA  in PBMCs [immunoglobulin arm +2.09 log10, control arm -3.10 log10 
copies/million CD4 cells (CI -2553,5363; p=0.38)] or low copy viral load (immunoglobulin arm 
+5.2 log10 copies/million CD4 cells; control arm  +12.25 log10 copies/million CD4 cells; (CI -
40.87,26.77; p=0.57). 
 
In the gut, total HIV DNA declined in both groups, with no significant differences between 
arms between w19 to w48 (immunoglobulin arm 4.72 log10, control arm -4.84 log10 
copies/million CD4 cells; p=0.55). Furthermore there was no difference in change in the 
number of CD4 T cells for w19 to w48 (immunoglobulin arm +2.87, control arm -6.07 cells; 
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p= 0.17] or in CD8 T cells for w19 to w48 [(immunoglobulin arm -4.53, control arm -1.53; p= 
0.60] in the gut over time (Table 2). 
 
- Bacterial translocation 
Bacterial translocation increased from w19 to w48 in the immunoglobulin arm (24.1 copies 
16SDNA/ml) and control arm (14.8 copies 16S DNA/ml) with no difference between the 
groups (CI -83.09, 101.87: p: 0.8)].  
 
- T-cell activation and exhaustion 
There were no significant changes from w19  to w48 in the level of activation of CD4 + T cells 
and CD8+ T cells  (% CD4CD25, % CD4CD38, % CD4CD69, % CD4 HLA DR, % CD8 HLA DR,  
CD8CD69, CD8CD38 and CD8CD25) or level of immune exhaustion of markers (Pd1 , Tim3 
Lag3) on CD4 + T cells and CD8+ T cells .   
 
Discussion 
The latent infection of resting CD4+ T-lymphocytes constitutes a major obstacle for the 
eradication of HIV. We sought to explore whether the temporary reduction in viral reservoir 
associated with immunoglobulin use in chronic infection [7,8] could induce a longer term 
effect in those treated at acute HIV infection before viral set point has been reached. 
 
Immunoglobulin therapy was well tolerated but did not induce any viral blips during therapy. 
We found no impact of immunoglobulin on viral reservoir in the blood or gut or any 
surrogate markers of HIV (including immune activation, immune exhaustion or bacterial 
translocation) from baseline to w48. The finding that such non-specific antibodies play no 
role in HIV cure is highly topical given that several HIV-specific monoclonal antibodies—in 
particular, PGT121, VRC01, and VRC03—do exhibit anti-latent viral reservoir properties [10, 
11] and clinical trials are underway.  
 
In this pilot study we did not detect a significant difference between the arms. However the 
small sample size may have limited the possibility of detecting differences. Moreover, 
whether a different timing on immunoglobulin administration (i.e. when patient first seen)  
would have reported different results remains unclear. 
The significant cost and invasiveness of the intervention may limit larger studies required to 
prove this intervention as an effective strategy. 
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The rapid recruitment to this study and the fact that all participants volunteered for the 
optional gut biopsies highlights the willingness of individuals with acute HIV infection to take 
part in HIV cure research. 
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Table 1: Baseline characteristics of participants 
 
 
 
Treatment (n=5)  Control (n=6)  
P-
value 
Gender: Male  5(100%) 6(100%) NA 
Ethnicity:  
- White  
- Black 
5(100%) 
0(0) 
5(83.33%) 
1(16.67%) 
1.00 
HIV Genotype:  
- Wild type virus  
5 6 1.00 
Age  31.2(3.3) 31.3(5.4) 0.96 
HIV Plasma Viral Load (log10 
copies/million CD4 cells) 
4.82(4.82) 6.28(6.48)  0.20 
CD4:CD8 0.71(0.35) 0.5(0.22) 0.3 
CD4 T cell count 678(218.75) 508.6(72.45) 0.16 
Total HIV DNA (log10 
copies/million CD4 cells) 
3.80(3.43) 4.04(3.74) 0.14 
Summary statistics are mean (SD) or count (%) as appropriate. 
 
 
 
 
 
Table 2 : Results: comparison between treatment and control group 
 Changes from week 19 to 48 
 Mean change  
 
treatment group 
n=5 
control group 
n=5 
difference between 
groups (95% CI) 
P-value 
Reservoir  
 
    
Total HIV DNA log10 
copies/million CD4 
cells in PBMCs 
2.09 -3.10 3.14 (-3.40, 3.72) 0.38 
Total HIV DNA log10 
copies/million CD4 
4.72 -4.84 5.09 (-5.54,5.77) 0.55 
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cells in gut 
Low copy RNA 
copies/ml  
5.2 12.25 -7.05(-40.87,26.77) 0.57 
     
Gut immunology     
CD4 cell number 2.87 -6.07 8.93(-5.09,22.96) 0.17 
CD8 cell number -4.53 -1.53 -3(-15.95,9.95) 0.6 
     
Microbial 
translocation 
    
16S RNA copy/nl  24.16 14.77 9.39(-83.09,101.87) 0.8 
     
Immune activation     
CD8+CD25+ 4.09 -0.88 4.97(-1.07,11) 0.08 
CD8+CD38+  18.25 5 13.25(-47.63,74.12) 0.5 
CD8+CD69+  4.63 0.58 4.04(-14.32,22.41) 0.46 
CD8+HLA.DR+ 2.14 -0.1 2.25(-7.54,12.03) 0.43 
CD4+CD25+ 13.18 5.95 7.23(-15.43,29.9) 0.19 
CD4+CD38+ 7.85 -4.6 12.45(-22.22,47.11) 0.3 
CD4+CD69+ 2.64 0.79 1.85(-7.82,11.52) 0.55 
CD4+HLA.DR+ 2.32 1.73 0.59(-4.06,5.24) 0.71 
     
Immune exhaustion     
CD8+ Lag3  0.55 -3.15 3.69(-19.28,26.67) 0.43 
CD8+ Pd1  5.81 3.96 1.85(-18.29,21.99) 0.79 
CD8+ Tim3  13.27 0.94 12.33(-26.82,51.48) 0.28 
CD4+ Lag3  0.76 -1.52 2.28(-7.79,12.36) 0.32 
CD4+ Pd.1  5.91 6.95 -1.04(-59.92,57.84) 0.89 
CD4+ Tim3  7.13 1.93 5.2(-21.09,31.49) 0.37 
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